Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -0.43% 116.50 176,011 08:46:57
Bid Price Offer Price High Price Low Price Open Price
115.00 118.00 118.50 114.50 118.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.51 -18.05 -12.98 294
Last Trade Time Trade Type Trade Size Trade Price Currency
08:47:27 O 1,500 115.92 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date Time Title Posts
30/11/202008:49Avacta – Innovative and Disruptive Technologies for Global Health Markets17,793
30/11/202000:00CV And The Deep State142
28/11/202017:12Covid-19. Ten Minute Test. Gamechanger!!17,812
28/11/202013:00avct The Fall!!!68
30/9/202012:10Ten Minutes to Save the World.55

Add a New Thread

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:47:27115.921,5001,738.80O
08:47:26115.9210,00011,592.00O
08:47:11115.882,9003,360.52O
08:46:45115.754,3295,010.82O
08:46:36115.904,3084,992.97O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
29/11/2020
08:20
Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 117p.
Avacta Group Plc has a 4 week average price of 90p and a 12 week average price of 90p.
The 1 year high share price is 215p while the 1 year low share price is currently 13.50p.
There are currently 252,652,554 shares in issue and the average daily traded volume is 5,429,273 shares. The market capitalisation of Avacta Group Plc is £295,603,488.18.
28/11/2020
12:20
tickboo: The Affimer platform is the differentiator and means they can be produced in expensively. Given nothing else has been published that as good as the ELISA test I assume the AVCT LFT will be best in class. The U.K. gov wants a sovereign supplier and it seems to me AVCT is a shoe-in. I am frustrated with the delay, no question but I was buying back in April and am still well in profit and yeah should've took sliced a while ago but I'm not selling as see a lot of upside. The same applies to SNG, I see a lot of upside there too and that's a broader therapy than just for COVID. Why I like AVCT and that's why they managed to rise so much cash for the therapeutic division. I think come early Jan (AVCT before) they'll be back to highs. FYI other large holding are DVRG and MIRI, both busy ends to the year and massive 2021 like AVCT andSNG.
26/11/2020
09:52
stmcn: Agree with JohnC here - the NYT article was shamelessly Az negative and pro-US firms (Pf and Mod - 'winning the race') - politics at the forefront here as the others need so much specialist equipment to move and store their materials - they have their own hills to climb....what a gunfight. Let's hope AVCT get their own act together shortly ....otherwise we will be waiting for the other threads (Precision Chemo) to make any money in the medium term. Not super happy about the share price but it does seem a firm base against recent RNS / delays (and they are delays now, albeit smallish...)...
24/11/2020
10:52
lithological heterogeneities: AVCT CEO says "major" news won't be longNothing has changed except we now have an extra anterior nasal test (not the brain picking uncomfortable one),we are half way through BAMS Trial and are one day closer to next piece of major news which AVCT CEO says will not be long so we might be in the the running for the £912m test as well which starts on 12 Dec which coincides with the UK Government Travel Minister saying this yesterday "Travel quarantine will be replaced by testing plan before Christmas"I am very confident AVCT will release "major" news soon as AVCT said it would be yesterday.A big few weeks ahead.
24/11/2020
09:38
viking24: What was interesting to see yesterday, was the post prints of the buying that had taken place during the day. Multiple lots of 50/ and one of 240/. Buying printed after hours was close to 1,9 mill shares!! The US buyer continues on a daily basis to pick up stock, knowing next RNS by second week in December the stock will be trading north of 200 and the company manufacturing BAMS which the government would have bought everything there was produced and then before Christmas we will have LFT being mass produced for professional use and the share price at 400pBased on the est monthly manufacturing capacity and est. consumer use of rapid testing, the share price should then be heading toward the original target price made by broker of 750
22/11/2020
15:05
lithological heterogeneities: £912m LFT antigen tender by this Wed, £912m tender for 3.5 months. Closing date on Wednesday this week. If,as I hope,the tender was extended from 13 to 25 November to allow time for AVCT to apply then it could be a very big week ahead for AVCT if they RNS that they have applied (unlikely I know). Would also explain the so-called "mystery rise" last week. Somebody ALWAYS knows. Fingers crossed anyway. "£912m tender, 3.5 months, LFT antigen test. hTtps://bidstats.uk/tenders/2020/W46/738656651 Lateral Flow Technology Testing Solutions Source: Contracts Finder Published: Tue 10 Nov 2020 Deadline: Wed 25 Nov 2020 Lateral flow tests are used for the rapid (typically 10-30 minutes) detection of a coronavirus antigen. The test strip itself is composed of a nitrocellulose membrane, retained within typically a plastic housing with a window at one end with a sample pad for the addition of the sample and a window at the other end showing a visual positive or negative result dependant on the presence of the virus." This sounds EXACTLY like the AVCT pregnancy style test to me that was explained by AVCT CEO Alistair Smith below (plastic housing,membrane,window at one end with a sample pad for the addition of the sample and a window at the other end showing a visual positive or negative result dependant on the presence of the virus.): Alistair Smith ,AVCT CEO How a Lateral Flow test works: hTtps://avacta.com/how-a-lateral-flow-rapid-test-works/
19/11/2020
09:03
capitalist: Morning grosstonage, I hear what you say about the lack of RNS when the share price plunged a few days ago. I think there is a slight difference between that fall and yesterday's jump. On the first occassion, almost all covid stocks (NCYT, SNG, ODX etc) fell similarly. Yesterday saw a 30% rise on AVCT without similar movements elsewhere. I am not an expert on RNS rules, but I had expected either a disclaimer RNS or a substantive RNS. Maybe as others are speculating, an RNS might come later in the day of course.
17/11/2020
13:59
thefartingcommie: hTTps://twitter.com/MylesMcNulty/status/1328669267299065856 I have had so many calls and messages about the fall in #AVCT @avacta 's share price over recent weeks. Let me be very clear: I am entirely unconcerned by this fall. As the below Tweet shows, I had a long-term target of ~£20 BEFORE Avacta announced its #COVID19 workstreams. The issue is - as is becoming more and more often the case in the world of micro-caps - people are buying companies like #AVCT without having first decided if it is a trade or an investment position. I cover the importance of this distinction in my profile picture. I myself am a trader, professionally, and actually hold very few long term investments. The volatility and lack of quality, accessible research renders AIM an excellent trading ground. But @avacta #AVCT is an investment. In the next few weeks, it'll be submitting .its CTA for the pro-dox trial, and top line data for that should come in July/August next year. If anyone can tell me more important clinical data for the welfare of mankind - to have ever been received by an AIM listed company - I am all ears. Even though it's just. Phase I, it is easy to appreciate how positive data would demand a valuation of multiples of #AVCT @avacta 's current mkt cap. Especially if it is listed on NASDAQ by then - which seems a reasonable assumption, given the recent US broker appointment. Over the next 7-8..months, until that top line data arrives, #AVCT will be selling #COVID19 diagnostics products in massive quantities, in my view. The market seems to have forgotten that Adeptrix is already selling the #COVID19 BAMS test, as RUO, in conjunction with MS specialist Bruker. Would these two really be marketing the BAMS test to customers, were it not already proven to be highly accurate? These sales are generating revs for #AVCT right now. Re: the critical product, the LFT: the delay, and thus the missed rev, has been the chief cause of dismay.for private investors. I am as frustrated as anyone that it has taken this long for @avacta and @bbi_solutions to complete the TT. Yet we continue to see other rapid antigen tests being ripped into by the science community for their poor quality. So it seems #AVCT is...perhaps doing the right thing, by aiming for perfection, prior to launching its LFT. The argument that angry PIs are proffering is: by striving for perfection, #AVCT has already missed out on hundreds of millions of pounds in revenue this year. That is true. But the...other side to the argument is that the market for #COVID19 rapid tests will be around for years, regardless of successful vaccines coming online. Heathrow's CEO seems to agree with this view of #AVCT's Alastair Smith, and not with angry PIs:Accordingly, by taking the time to develop a first-in-class rapid antigen LFT - that can be bought by individuals for their medicine cabinets, and be the go-to diagnostic for doctors in hospitals and GPs - @avacta #AVCT is essentially sacrificing several hundred millions ..in revenue this year, for perhaps billionsThis impending revenue from its various #COVID19 diagnostic products will fund the development of #ACT's Therapeutics div - which itself has the potential to reshape the landscape of oncology. No more equity dilution, and financing multiple clinical studies simultaneously. in revenue over the next three years. #AVCT has very recently stated that it'll be commencing clinical validation for its LFT shortly. Retail investors simply need to exercise patience. Personally, I think that right now, at 102p / £260m mkt cap, #AVCT is the cheapest it's ever, ever been. As such, I have been more shares today in family accounts to hold for the longer term.
11/11/2020
21:09
lithological heterogeneities: IPO Admission Document will contain alot of detail about mass production of AVCT tests causing a rise in AVCT share price and a massively oversubscibed IPO.
10/11/2020
08:28
johnnyb1: Well, this looks more exciting than ever!Two flash crashes pre-news, clearing out a lot of leveraged and loose holders that would drag on the share price Perhaps there will be some stragglers selling today but it will be short-lived and a shake-out is healthy. Taking a step back and looking at the bigger picture...A lot of realism kicking in now around the details of the Pfizer announcement. Very early in the trials program for Pfizer to release that announcement and it could come back to haunt the CEO. Perhaps he needed to get something out to relieve pressure from his Board and shareholders after committing $1.5Bn of company money without taking any US Govt assistance. Vaccines still have a long way to go in terms of approvals and scaling and even further to go in getting to the Covid frontline. Testing is required in huge volumes for several years to come and no likelihood of achieving herd immunity through vaccination in even the most advanced countries until 2022...and only IF ALL of the vaccines in development are successfull and there are NO delays in safety, licensing, manufacture and production. Those are long odds, so more likely we are looking at 2023 and beyond. One also has to reflect on national Governments imperative to get the economy moving as quickly as possible or risk a global depression. The fractional distribution of these limited vaccine supplies will be aimed at the elderly and those on the frontline of healthcare. Not the workers and tax-payers who drive the economy. Think about that...the recipients of all of the early vaccine distribution will NOT be the Net Contributors to the treasury.In order to get those people back to normality within the next 12-24 months, there is only one solution. Mass testing.So, in my view the only thing that has changed is the improved chances of this stock rising on news due to the shake-out of highly speculative and leveraged traders waiting to sell into news. So what about news. I suspect it is close. I admit, I have been somewhat surprised by the snails pace (going backward) of tech transfer and validation in the midst of a national emergency. However, the signs which have been well documented on these boards, all indicate toward AVCT now being one of the main choices for the UK and, in time, other governments around the world. Thomas Fuller - "The darkest hour is just before the dawn"
04/11/2020
14:31
ambyth: So, the fact is there only 2 routes for tests to UK Government approval and use, via CONDOR and via Porton Down: 1. CONDOR - painfully slow “A snail going backwards”: We know AVCT is in this process along with many other tests. We know Mologic has been involved with CONDOR (they were involved in pilot testing at Heathrow on the public, along with I-abra and Geneme, over 2 months ago on 29th August. Https://mologic.co.uk/mologic-covid-19-testing-at-heathrow-airport/ We now see Mologic’s test as very much the most likely one involved in Liverpool’s massive 2 week pilot testing trial on 500,000 members of public with combination of available existing PCR tests, LAMP tests and LFT tests. Note: Mologic is the company Boris visited way back on 6th March and found £1m investment for: Https://www.bbc.co.uk/news/uk-51771116 2. Porton Down: We know AVCT is not in this process, and only 3 tests have been chosen for progress (SD Biosensor, Innova, Healgen) Estimate this takes at least 2 months based on updates dates on the 3 tests as they were updated. Https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results The big problem we have for AVCT is right now we just simply don’t have an actual test to even trial. Other companies have been, and are, testing on the public in pilot trials and sharing data with Government. We just seem to be well behind the curve and no news at all. Hoping a miracle rabbit gets pulled out of a giant hat for AVCT somehow, but the facts point to it being less and less likely.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201130 09:02:40